Paper Details

  1. Home
  2. Paper Details

Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial.

Author: , BesselinkM G, BonsingB A, BosH, BosschaK P, CoeneP P L O, Groot KoerkampB, HomsM Y V, JanssenQ P, KarstenT M, LiemM S L, LoosveldO J L, PatijnG A, WilminkJ W, ZonderhuisB M, de HinghI H J T, de Vos-GeelenJ, van DamJ L, van EijckC H J, van SantvoortH C, van TienhovenG, van der KolkM B

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Clinical Trial ProtocolA plan for conducting a clinical trial. It describes in detail the purpose, design, methodology, and statistical considerations of the trial, ensuring the transparency and consistency of the trial.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Neoadjuvant therapy may improve overall survival in patients with localized pancreatic cancer, but randomized trials are needed to confirm its effectiveness.
Paper Details　
Original Abstract of the Article :
Neoadjuvant therapy has several potential advantages over upfront surgery in patients with localized pancreatic cancer; more patients receive systemic treatment, fewer patients undergo futile surgery, and R0 resection rates are higher, thereby possibly improving overall survival (OS). Two recent ran...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7989075/

データ提供：米国国立医学図書館（NLM）

Pancreatic Cancer: A New Path Through the Desert of Treatment

The desert of pancreatic cancer, like a formidable landscape, presents significant challenges for those seeking effective treatment. This study, like a team of researchers embarking on a groundbreaking expedition, investigates the potential of neoadjuvant FOLFIRINOX, a multi-agent chemotherapy regimen, as a new treatment option for pancreatic cancer. The researchers, like skilled desert engineers, design a nationwide multicenter randomized controlled trial (RCT) to compare the efficacy of neoadjuvant FOLFIRINOX with conventional chemoradiotherapy approaches.

FOLFIRINOX: A Potential Oasis in the Desert of Pancreatic Cancer

This study's findings, like a well-worn path leading to a hidden oasis, are anticipated to provide valuable insights into the potential of neoadjuvant FOLFIRINOX in treating pancreatic cancer. The researchers, like meticulous desert cartographers, are carefully mapping the landscape of treatment options, seeking to improve outcomes for patients with this challenging disease.

Navigating Pancreatic Cancer: Embracing New Treatment Options

This research, like a beacon of hope in the desert, holds the promise of offering new and potentially more effective treatment options for individuals battling pancreatic cancer. The study's findings, like a valuable oasis resource, could lead to improved survival rates, reduced complications, and a better quality of life for patients.

Dr. Camel's Conclusion

This study, like a journey through a challenging desert, represents a significant step forward in the fight against pancreatic cancer. The researchers, like dedicated desert guides, are committed to finding innovative solutions that can improve the lives of those affected by this devastating disease. As we continue our research journey, we are hopeful that this study will lead to a new oasis of hope and healing for patients with pancreatic cancer.

Date :
  1. Date Completed 2021-05-10
  2. Date Revised 2022-12-07
Further Info :

Pubmed ID

33757440

DOI: Digital Object Identifier

PMC7989075

Related Literature

Article Analysis
・Effective treatment of pancreatic cancer
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.